UCB PHARMA

Active

Public limited companyfounded 196858 yrs activeResearchdreef 60, 1070 Anderlecht, BelgiumKBO/BCE: BE 0403.096.168

Summary

UCB PHARMA has been active since 1968 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.23B and a net result of €4.24B. Equity is growing by ~16% per year across the filed fiscal years. Its solvency ranks better than 84% of 4867 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Watch Print / PDF

Checked score

Score 2025

75 / 100

Excellent

The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability68▼-16

Solvency100=

Growth72▲+1

Track record100

Bankruptcy probability, 12 months

0.5% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €2M at 30 days acceptable

Liquidity ample (current ratio 1.6 against 1.81 in 2024; short-term debt: 10.9% and cash: 0% of total assets), and 21.7% of the assets are financed with debt.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

78.3%

Return on assets

20.4%

Age of the figures

9 mo

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Multiple establishment units

Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.

KBO · establishment units

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Sector 46

higher

← fewer bankruptcies more bankruptcies →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-05-2026, 73 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

73 d early

2024

73 d early

2023

6 d late

2022

75 d early

2021

69 d early

2020

92 d early

2019

74 d early

← before the deadline after the deadline →

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

24-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover

€4.62B▲ 9.8%

2024 · €4.21B

2018: €2.69B 2019: €3.25B 2020: €3.87B 2021: €3.43B 2022: €3.30B 2023: €3.18B 2024: €4.21B

2018 → 2025

EBIT margin

7.2%▼ 17.2pp

2024 · 24.4%

2018: 18.2% 2019: 21.9% 2020: 16.4% 2021: 19.5% 2022: 29.9% 2023: 27.5% 2024: 24.4%

2018 → 2025

Net result

€4.24B▲ 347%

2024 · €947.43M

2018: €439.61M 2019: €444.34M 2020: €574.82M 2021: €612.59M 2022: €948.10M 2023: €938.12M 2024: €947.43M

2018 → 2025

Working capital

€1.37B▼ 5.6%

2024 · €1.45B

2018: €-869.06M 2019: €-912.51M 2020: €137.91M 2021: €463.06M 2022: €903.17M 2023: €1.54B 2024: €1.45B

2018 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20212022202320242025Trend

Turnover€3.43B-€3.30B▼ 4.0%€3.18B▼ 3.6%€4.21B▲ 32.6%€4.62B▲ 9.8%

Equity€9.74B-€11.21B▲ 15.1%€11.80B▲ 5.2%€12.40B▲ 5.1%€16.23B▲ 31.0%

Operating result€668.86M-€985.68M▲ 47.4%€872.81M▼ 11.5%€1.03B▲ 17.7%€334.67M▼ 67.4%

Net result€612.59M-€948.10M▲ 54.8%€938.12M▼ 1.1%€947.43M▲ 1.0%€4.24B▲ 347%

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 67% below 2024 and is the lowest result in the available series.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €20.74B

82.5%

17.5%

Fixed assets €17.11B ▲ 29.7%

Current assets €3.63B ▲ 12.6%

Equity and liabilities €20.74B

78.3%

21.1%

Equity €16.23B ▲ 31.0%

Provisions €136.49M ▲ 55.9%

Debt €4.37B ▲ 11.2%

Debt's share of the balance-sheet total falls from 24.0% to 21.1%. Equity and debt are higher.

Key figures and ratios

2025 value · change against 2024

EBITDA

€410.52M▼

2024 · €1.08B

Cash flow

€4.32B▲

2024 · €1.00B

Current ratio

1.60▼

2024 · 1.81

Quick ratio

1.09▼

2024 · 1.20

Debt to equity

0.27▼

2024 · 0.32

ROE

26.1%▲

2024 · 7.6%

ROA

20.4%▲

2024 · 5.8%

Interest coverage

3.65▼

2024 · 7.52

Debt ≤ 1 year

€2.27B▲

2024 · €1.78B

Debt > 1 year

€2.09B▼

2024 · €2.11B

Income taxes

€-131k▼

2024 · €143.55M

Staff costs

€291.34M▲

2024 · €249.70M

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2025 against 2024 · 103 lines

Balance sheet Code20242025

Assets

Total assets20/58€16.41B€20.74B▲

Fixed assets21/28€13.19B€17.11B▲

Intangible fixed assets21€8.84M€8.38M▼

Tangible fixed assets22/27€975.35M€1.08B▲

Land and buildings22€203.67M€412.94M▲

Plant, machinery and equipment23€107.77M€282.71M▲

Furniture and vehicles24€4.09M€6.69M▲

Other tangible fixed assets26€9.70M€8.03M▼

Assets under construction and advance payments27€650.12M€364.89M▼

Financial fixed assets28€12.20B€16.03B▲

Affiliated companies280/1€12.20B€16.03B▲

Participating interests280€12.20B€16.03B▲

Current assets29/58€3.23B€3.63B▲

Stocks and contracts in progress3€1.08B€1.15B▲

Stocks30/36€1.08B€1.15B▲

Raw materials and consumables30/31€123.26M€172.80M▲

Work in progress32€5.63M€4.19M▼

Finished goods33€955.62M€976.70M▲

Goods purchased for resale34€34k€12k▼

Amounts receivable within one year40/41€2.03B€2.36B▲

Trade receivables40€1.19B€1.37B▲

Other amounts receivable41€843.57M€995.64M▲

Cash at bank and in hand54/58€11.06M€7.87M▼

Deferred charges and accrued income490/1€102.57M€108.41M▲

Equity and liabilities

Total equity and liabilities10/49€16.41B€20.74B▲

Equity10/15€12.40B€16.23B▲

Contributions10/11€7.80B€7.80B=

Capital10€7.80B€7.80B=

Issued capital100€7.80B€7.80B=

Outside capital11€12€12=

Share premium1100/10€12€12=

Reserves13€325.14M€780.64M▲

Non-distributable reserves130/1€324.58M€780.48M▲

Legal reserve130€324.58M€780.48M▲

Other1319€3k€3k=

Tax-exempt reserves132€556k€163k▼

Profit (loss) carried forward14€4.27B€7.65B▲

Provisions and deferred taxes16€87.56M€136.49M▲

Provisions for liabilities and charges160/5€87.16M€136.22M▲

Major repairs and maintenance162€17.01M€22.80M▲

Environmental obligations163€19.73M€21.26M▲

Other liabilities and charges164/5€50.42M€92.15M▲

Deferred taxes168€404k€273k▼

Amounts payable17/49€3.93B€4.37B▲

Amounts payable after more than one year17€2.11B€2.09B▼

Financial debts170/4€2.10B€2.08B▼

Other loans174€2.10B€2.08B▼

Other amounts payable178/9€9.60M€8.13M▼

Amounts payable within one year42/48€1.78B€2.27B▲

Financial debts43€305.15M€12.28M▼

Credit institutions430/8€19.64M€1.96M▼

Other loans439€285.51M€10.32M▼

Trade debts44€977.82M€1.74B▲

Suppliers440/4€977.82M€1.74B▲

Taxes, remuneration and social security45€102.23M€72.67M▼

Taxes450/3€66.22M€30.49M▼

Remuneration and social security454/9€36.01M€42.18M▲

Other amounts payable47/48€394.05M€437.76M▲

Accrued charges and deferred income492/3€39.36M€19.99M▼

Income statement Code20242025

Operating income70/76A€5.88B€6.23B▲

Turnover70€4.21B€4.62B▲

Change in stocks of work in progress, finished goods and contracts in progress71€253.60M€19.64M▼

Own construction capitalised72€15.96M€23.38M▲

Other operating income74€1.40B€1.56B▲

Non-recurring operating income76A€53k€18k▼

Operating charges60/66A€4.85B€5.89B▲

Goods for resale, raw materials and consumables60€1.17B€1.21B▲

Purchases600/8€1.18B€1.28B▲

Change in stocks: decrease (increase)609€-6.92M€-68.93M▼

Services and other goods61€3.32B€4.22B▲

Remuneration, social security and pensions62€249.70M€291.34M▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€55.17M€75.85M▲

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€6.02M€15.94M▲

Provisions for liabilities and charges: additions (uses and reversals)635/8€24.46M€24.68M▲

Other operating charges640/8€22.55M€26.66M▲

Non-recurring operating charges66A€-120k€19.75M▲

Operating profit (loss)9901€1.03B€334.67M▼

Financial income75/76B€395.84M€4.03B▲

Recurring financial income75€388.17M€210.04M▼

Income from financial fixed assets750€216.41M€110.00M▼

Income from current assets751€44.86M€17.04M▼

Other financial income752/9€126.91M€83.01M▼

Non-recurring financial income76B€7.67M€3.82B▲

Financial charges65/66B€332.46M€128.10M▼

Recurring financial charges65€310.07M€128.10M▼

Debt charges650€143.93M€112.50M▼

Other financial charges652/9€166.14M€15.60M▼

Non-recurring financial charges66B€22.39M-

Profit (loss) for the period before taxes9903€1.09B€4.24B▲

Transfer from deferred taxes780€131k€131k=

Income taxes67/77€143.55M€-131k▼

Taxes670/3€143.58M€28.19M▼

Tax adjustments and reversals of tax provisions77€39k€28.32M▲

Profit (loss) for the period9904€947.43M€4.24B▲

Transfer from tax-exempt reserves789€393k€393k=

Profit (loss) for the period to be appropriated9905€947.82M€4.24B▲

Appropriation of the result

Profit (loss) to be appropriated9906€4.66B€8.51B▲

Profit (loss) brought forward from the previous period14P€3.71B€4.27B▲

Transfer to equity691/2€47.39M€455.90M▲

To the legal reserve6920€47.39M€455.90M▲

Profit to be distributed694/7€350.00M€400.00M▲

Return on contributions (dividend)694€350.00M€400.00M▲

Social balance

Average headcount (FTE)90871,746.41,960.6▲

The notes to these accounts (89 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 65Financial 4Gazette 51Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

10-09

State Gazette act Appointment: Jacques Marbehant (director)

Resignation: Kirsten Lund-Jurgensen (director)3 facts ▸

General meeting, 13-05-2026
Director appointment, Jacques Marbehant (director)
Director resignation, Kirsten Lund-Jurgensen (director)

19-05

NBB filing Annual accounts filed

fiscal year 2025 · full schema

2025

31-12

Financial Highest result since 2018net €4.24B ▲347%

Net result €4.24B, the highest in the series.

17-10

State Gazette act Resignations & appointments

Power of attorney30 facts ▸

Board meeting, 31/03/2025
Power of attorney, Ann Gudiens
Power of attorney, Bram De Pooter
Power of attorney, Alexandra Nijssen
Power of attorney, Laetitia Munoko
Power of attorney, Natacha Tassier
Power of attorney, Loïc Petit
Power of attorney, Blerta Aliaj
Power of attorney, Olivier Bruneel
Power of attorney, Sébastien Lair
Power of attorney, Anke Sanders
Power of attorney, Laurent Simonart
+18 further facts in this act

19-05

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

26-08

State Gazette act Appointments: Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL (commissaire aux comptes) and Myriam Juckler (déléguée chargée de la gestion journalière)

Permanent representative: Sébastien Schueremans · Resignation: Jacques Marbehant (daily management delegate)6 facts ▸

General meeting, 08/05/2024
Board meeting, 26/07/2024
Auditor appointment, Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL (commissaire aux comptes)
Permanent representative, Sébastien Schueremans
Director appointment, Myriam Juckler (déléguée chargée de la gestion journalière)
Director resignation, Jacques Marbehant (daily management delegate)

06-08

NBB filing Annual accounts filed

fiscal year 2023 · full schema · 6 days late

2023

04-08

State Gazette act Resignations & appointments

Power of attorney · Mandate term31 facts ▸

Board meeting, 22-06-2023
Power of attorney, Ann Gudiens
Power of attorney, Bram De Pooter
Power of attorney, Alexandra Nijssen
Power of attorney, Jessica Pierre
Power of attorney, Joelle Coldrick
Power of attorney, Olivier Bruneel
Power of attorney, Blerta Aliaj
Power of attorney, Laetitia Munoko Mubolo
Power of attorney, Natacha Tassier
Power of attorney, Laurent Simonart
Power of attorney, Alexandra Nijssen
+19 further facts in this act

04-08

State Gazette act Reappointments: Jean-Christophe Tellier (director) and Charl van Zyl (director)

Resignation: Charl van Zyl (director)5 facts ▸

General meeting, 10/05/2023
Director reappointment, Jean-Christophe Tellier (director)
Director reappointment, Charl van Zyl (director)
General meeting, 25/07/2023
Director resignation, Charl van Zyl (director)

17-05

NBB filing Annual accounts filed

fiscal year 2022 · full schema

2022

31-12

Financial Equity above €10000MEq €11.21B ▲15.1%

5 profitable years in a row build equity to €11.21B.

28-07

State Gazette act Capital & shares

Capital increase · Capital · Power of attorney4 facts ▸

Capital increase, €819.225.260,4
Capital, €7.804.773.797,45
Power of attorney, Stéphanie Ernaelsteen
Power of attorney, Daphné Bosnic

Show earlier events

23-06

State Gazette act Reappointments: Kirsten Lund-Jürgensen (director) and Caroline Vancoillie (director)

Mandate compensation5 facts ▸

General meeting, 11/05/2022
Director reappointment, Kirsten Lund-Jürgensen (director)
Director reappointment, Caroline Vancoillie (director)
Mandate compensation, Kirsten Lund-Jürgensen
Mandate compensation, Caroline Vancoillie

23-05

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

09-07

State Gazette act Resignations & appointments

Power of attorney · Mandate term29 facts ▸

Board meeting, 01/04/2021
Power of attorney, Ann Gudiens
Power of attorney, Bram De Poorter
Power of attorney, Alexandra Nijssen
Power of attorney, Jessica Pierre
Power of attorney, Joelle Coldrick
Power of attorney, Olivier Bruneel
Power of attorney, Blerta Aliaj
Power of attorney, Laurent Simonart
Power of attorney, Alexandra Nijssen
Power of attorney, Sylvie Rauel-Rasmussen
Power of attorney, Geoffrey Folie
+17 further facts in this act

09-07

State Gazette act Resignations & appointments

Power of attorney28 facts ▸

Board meeting, 01/04/2021
Power of attorney, Ann Gudiens
Power of attorney, Bram De Pooter
Power of attorney, Alexandra Nijssen
Power of attorney, Jessica Pierre
Power of attorney, Joelle Coldrick
Power of attorney, Olivier Bruneel
Power of attorney, Blerta Aliaj
Power of attorney, Laurent Simonart
Power of attorney, Alexandra Nijssen
Power of attorney, Sylvie Rauel-Rasmussen
Power of attorney, Geoffroy Folie
+16 further facts in this act

30-04

NBB filing Annual accounts filed

fiscal year 2020 · full schema

22-01

State Gazette act Capital & shares · Miscellaneous

Capital1 fact ▸

Capital, €6.985.548.537,05

2020

31-12

Financial Equity above €5000MEq €9.33B ▲211%

3 profitable years in a row build equity to €9.33B.

30-12

State Gazette act Capital & shares · Statutes amendment

Capital increase · Share issue · Capital6 facts ▸

General meeting, 18 décembre 2020
Capital increase, €5.751.269.288,48
Share issue, 691.046.183, e2
Capital, €6.985.548.537,05
Statutes amendment
Power of attorney, conseil d'administration

12-11

State Gazette act Appointment: Geoffroy Folie (délégué chargé de la gestion journalière)

Resignation: Eric Browaeys (daily management delegate)3 facts ▸

Board meeting, 16/10/2020
Director appointment, Geoffroy Folie (délégué chargé de la gestion journalière)
Director resignation, Eric Browaeys (daily management delegate)

23-06

State Gazette act Reappointments: Jean-Christophe Tellier (director) and Charl van Zyl (director)

Mandate compensation5 facts ▸

General meeting, 13/05/2020
Director reappointment, Jean-Christophe Tellier (director)
Director reappointment, Charl van Zyl (director)
Mandate compensation, Jean-Christophe Tellier
Mandate compensation, Charl van Zyl

18-05

NBB filing Annual accounts filed

fiscal year 2019 · full schema

02-01

State Gazette act Appointment: Jacques Marbehant (délégué chargé de la gestion journalière)

2 facts ▸

Board meeting, 22/11/2019
Director appointment, Jacques Marbehant (délégué chargé de la gestion journalière)

2019

31-12

Financial Equity above €2500MEq €3.00B ▲27.6%

2 profitable years in a row build equity to €3.00B.

23-08

State Gazette act Appointment: Kirsten LUND-JÜRGENSEN (administrateur additionnel)

Mandate compensation3 facts ▸

General meeting, 18/07/2019
Director appointment, Kirsten LUND-JÜRGENSEN (administrateur additionnel)
Mandate compensation, Kirsten LUND-JÜRGENSEN

07-06

State Gazette act Resignation: Cleo Ricci (director)

Reappointment: Caroline Vancoillie (director) · Mandate compensation6 facts ▸

Board meeting, 09/04/2019
General meeting, 08/05/2019
Director resignation, Cleo Ricci (director)
Director resignation, Cleo Ricci (gérant chargé de la gestion journalière)
Director reappointment, Caroline Vancoillie (director)
Mandate compensation, Caroline Vancoillie

10-05

NBB filing Annual accounts filed

fiscal year 2018 · full schema

03-05

State Gazette act Capital & shares

Capital increase · Capital · Power of attorney5 facts ▸

Capital increase, €305.116.347,97
Capital, €1.234.279.248,57
Power of attorney, Stéphanie Ernaelsteen
Power of attorney, Anne-Catherine Guiot
Power of attorney, UCB PHARMA

05-02

State Gazette act Resignation: Benoit Stevens (daily management delegate)

2 facts ▸

Board meeting, 26/11/2018
Director resignation, Benoit Stevens (daily management delegate)

2018

27-08

State Gazette act Resignation: Benoit Stevens (director)

Appointments: Caroline Vancoillie (director) and SCCRL PwC Reviseurs d'Entreprises (statutory auditor) · Permanent representative: Romain Seffer5 facts ▸

General meeting, 09-05-2018
Director resignation, Benoit Stevens (director)
Director appointment, Caroline Vancoillie (director)
Auditor appointment, SCCRL PwC Reviseurs d'Entreprises (statutory auditor)
Permanent representative, Romain Seffer

28-05

NBB filing Annual accounts filed

fiscal year 2017 · full schema

2017

25-09

State Gazette act Resignation: Fabrice Enderlin (director)

2 facts ▸

General meeting, 29/08/2017
Director resignation, Fabrice Enderlin (director)

30-05

State Gazette act Reappointment: Jean-Christophe Tellier (director)

Appointment: Charl van Zyl (director) · Mandate compensation5 facts ▸

General meeting, 10/05/2017
Director reappointment, Jean-Christophe Tellier (director)
Director appointment, Charl van Zyl (director)
Mandate compensation, Jean-Christophe Tellier
Mandate compensation, Charl van Zyl

22-05

NBB filing Annual accounts filed

fiscal year 2016 · full schema

17-02

State Gazette act Resignation: Mark McDade (director)

2 facts ▸

Board meeting, 16/12/2016
Director resignation, Mark McDade (director)

2016

11-04

State Gazette act Capital & shares · Resignations & appointments

Capital increase · Capital · Power of attorney5 facts ▸

Capital increase, €234.701.369,6
Capital, €929.162.900,6
Power of attorney, Stéphanie Ernaelsteen
Power of attorney, Anne-Catherine Guiot
Statutes amendment

01-02

State Gazette act Resignations: Anna S. Richo, Ismail Kola and Detlef Thielgen

Appointments: Benoit Stevens (director) and Cleo Ricci (director) · Mandate compensation8 facts ▸

General meeting, 15/01/2016
Director resignation, Anna S. Richo (director)
Director resignation, Ismail Kola (director)
Director resignation, Detlef Thielgen (director)
Director appointment, Benoit Stevens (director)
Director appointment, Cleo Ricci (director)
Mandate compensation, Benoit Stevens
Mandate compensation, Cleo Ricci

2015

09-06

State Gazette act Appointments: Eric Browaeys (délégué chargé de la gestion journalière) and SC SRL PwC Reviseurs d'Entreprises (statutory auditor)

Resignations: Jean-Christophe Donck (délégué chargé de la gestion journalière) and Nunzio Antonelli (director) · Reappointments: Detlef Thielgen (director) and Ismail Kola (director) · Permanent representative: Romain Seffer11 facts ▸

Board meeting, 30/03/2015
General meeting, 13/05/2015
Director appointment, Eric Browaeys (délégué chargé de la gestion journalière)
Director resignation, Jean-Christophe Donck (délégué chargé de la gestion journalière)
Director resignation, Nunzio Antonelli (director)
Director reappointment, Detlef Thielgen (director)
Director reappointment, Ismail Kola (director)
Mandate compensation, Detlef Thielgen
Mandate compensation, Ismail Kola
Auditor appointment, SC SRL PwC Reviseurs d'Entreprises (statutory auditor)
Permanent representative, Romain Seffer

2014

10-06

State Gazette act Resignation: Frédéric Roch Doliveux (director)

Appointment: Jean-Christophe Tellier (director) · Reappointments: Jean-Christophe Tellier, Fabrice Enderlin and 2 others · Mandate compensation11 facts ▸

General meeting, 14/05/2014
Director resignation, Frédéric Roch Doliveux (director)
Director appointment, Jean-Christophe Tellier (director)
Director reappointment, Jean-Christophe Tellier (director)
Director reappointment, Fabrice Enderlin (director)
Director reappointment, Nunzio Antonelli (director)
Director reappointment, Mark McDade (director)
Mandate compensation, Jean-Christophe Tellier
Mandate compensation, Fabrice Enderlin
Mandate compensation, Nunzio Antonelli
Mandate compensation, Mark McDade

31-03

State Gazette act Resignation: Frédéric Roch Doliveux (director)

Appointment: Jean-Christophe Tellier (director) · Mandate compensation4 facts ▸

Board meeting, 17/03/2014
Director resignation, Frédéric Roch Doliveux (director)
Director appointment, Jean-Christophe Tellier (director)
Mandate compensation, Jean-Christophe Tellier

2013

22-10

State Gazette act Resignations & appointments

Power of attorney3 facts ▸

Power of attorney, Allen E. NORRIS
Power of attorney, Stéphane DROUIN
Power of attorney, Anna S. Richo

12-04

State Gazette act Resignations & appointments

Power of attorney4 facts ▸

Board meeting, 15/03/2013
Power of attorney, Robert J. Trainor
Power of attorney, Anna S. Richo
Power of attorney, Allen E. Norris

18-02

State Gazette act Resignation: Robert Trainor (director)

Appointment: Anna S. Richo (director)3 facts ▸

General meeting, 17/01/2013
Director resignation, Robert Trainor (director)
Director appointment, Anna S. Richo (director)

2012

11-06

State Gazette act Reappointments: Frédéric Roch Doliveux, Ismail Kola and 2 others

Appointment: PwC Reviseurs d'Entreprises SCCRL (statutory auditor) · Permanent representative: Jean Fossion · Mandate compensation11 facts ▸

General meeting, 09/05/2012
Director reappointment, Frédéric Roch Doliveux (director)
Director reappointment, Ismail Kola (director)
Director reappointment, Detlef Thielgen (director)
Director reappointment, Robert Trainor (director)
Mandate compensation, Frédéric Roch Doliveux
Mandate compensation, Ismail Kola
Mandate compensation, Detlef Thielgen
Mandate compensation, Robert Trainor
Auditor appointment, PwC Reviseurs d'Entreprises SCCRL (statutory auditor)
Permanent representative, Jean Fossion

03-05

State Gazette act Resignations: Iris Löw-Friedrich (director) and Christian Capouillez (daily management delegate)

Appointments: Benoit Stevens (daily management delegate) and Cleo Ricci (daily management delegate)5 facts ▸

Board meeting, 26/03/2012
Director resignation, Iris Löw-Friedrich (director)
Director appointment, Benoit Stevens (daily management delegate)
Director resignation, Christian Capouillez (daily management delegate)
Director appointment, Cleo Ricci (daily management delegate)

2011

27-05

State Gazette act Reappointments: Iris Loëw-Fredrich, Mark McDade and 2 others

Mandate compensation6 facts ▸

General meeting, 11/05/2011
Director reappointment, Iris Loëw-Fredrich (director)
Director reappointment, Mark McDade (director)
Director reappointment, Nunzio Antonelli (director)
Director reappointment, Fabrice Enderlin (director)
Mandate compensation, UCB Pharma S.A.

2010

17-06

State Gazette act Capital & shares

Approval2 facts ▸

General meeting, 25/05/2010
Approval, convention d'emprunt obligataire subordonné intervenue entre la Société et la Société Régionale d'Investissement de Wallonie, en abrégé "S.R.I.W.", société anon…

17-06

State Gazette act Resignation: William Robinson (director)

Appointment: Ismail Kola (director) · Mandate compensation4 facts ▸

General meeting, 25/05/2009
Director resignation, William Robinson (director)
Director appointment, Ismail Kola (director)
Mandate compensation, Ismail Kola

04-06

State Gazette act Capital & shares · Statutes amendment

Capital increase · Capital decrease · Capital8 facts ▸

General meeting, 12 mai 2010
Capital increase, €500.000.000
Capital decrease, €198.583.094
Capital, €694.461.531
Statutes amendment
Power of attorney, Conseil d'administration
Power of attorney, Stéphanie Emaelsteen
Power of attorney, Catherine Lelong

12-01

State Gazette act Appointment: Ismail Kola (director)

2 facts ▸

Board meeting, 08/12/2009
Director appointment, Ismail Kola (director)

2009

27-08

State Gazette act Appointment: Jean-Christophe Donck (délégué chargé de la gestion journalière)

Resignation: François Thys (délégué chargé de la gestion journalière)3 facts ▸

Board meeting, 25/06/2009
Director appointment, Jean-Christophe Donck (délégué chargé de la gestion journalière)
Director resignation, François Thys (délégué chargé de la gestion journalière)

15-06

State Gazette act Capital & shares · Statutes amendment

Capital increase · Capital decrease · Power of attorney3 facts ▸

Capital increase, €359.000.000
Capital decrease, €359.000.000
Power of attorney, Conseil d'administration

27-03

State Gazette act Capital & shares · Miscellaneous

Shareholder resolution1 fact ▸

Shareholder resolution, 16/03/2009

2008

20-10

State Gazette act Statutes amendment

Power of attorney4 facts ▸

Statutes amendment
Power of attorney, Conseil d'administration
Power of attorney, Stéphanie Emaelsteen
Meeting date, 10-10-2008

27-08

State Gazette act Resignations: Luc Missorten (director) and Jean-Pierre Pradier (director)

Appointments: Iris Löw-Friedrich (director) and Fabrice Enderlin (director) · Mandate compensation7 facts ▸

General meeting, 13/05/2008
Director resignation, Luc Missorten (director)
Director resignation, Jean-Pierre Pradier (director)
Director appointment, Iris Löw-Friedrich (director)
Director appointment, Fabrice Enderlin (director)
Mandate compensation, Iris Löw-Friedrich
Mandate compensation, Fabrice Enderlin

20-06

State Gazette act Capital & shares · Miscellaneous

Approval2 facts ▸

General meeting, 13/05/2008
Approval, contrat de licence et de distribution intervenu entre Chiesi Farmaceutici S.p.A. et la Société, daté du 16 mars 2007 concernant le produit Inuvair

20-06

State Gazette act Capital & shares · Miscellaneous

Approval2 facts ▸

General meeting, 13/05/2008
Approval, contrat de licence et de distribution intervenu entre Chiesi Farmaceutici S.p.A. et la Société, daté du 16 mars 2007

2007

08-06

State Gazette act Appointment: Daniel Goossens (statutory auditor)

2 facts ▸

General meeting, 09/05/2007
Auditor appointment, Daniel Goossens (statutory auditor)

26-03

State Gazette act Capital & shares · Statutes amendment

Statutes amendment · Power of attorney3 facts ▸

General meeting, 28 février 2007
Statutes amendment
Power of attorney, Conseil d'administration

2006

28-04

State Gazette act Resignation: Luc Vermeesch (director)

Appointment: Didier Malherbe (director) · Reappointment: Simon Looman (director) · Mandate compensation7 facts ▸

General meeting, 21 mars 2006
Board meeting, 23 février 2006
Director resignation, Luc Vermeesch (director)
Director appointment, Didier Malherbe (director)
Director reappointment, Simon Looman (director)
Director appointment, Didier Malherbe (managing director)
Mandate compensation, UCB PHARMA

2005

03-08

State Gazette act Resignation: Luc Vermeesch (manager qui assurera la gestion journalière)

Appointment: Nicolas Gouwy (manager qui assurera la gestion journalière)3 facts ▸

Board meeting, 16/02/2005
Director resignation, Luc Vermeesch (manager qui assurera la gestion journalière)
Director appointment, Nicolas Gouwy (manager qui assurera la gestion journalière)

09-05

State Gazette act Appointments: Guido Van Dingenen (administrateur supplémentaire) and Luc Vermeesch (director)

Reappointment: Philippe Proost (director) · Resignation: Frédéric Roch Doliveux (director) · Mandate compensation8 facts ▸

General meeting, 15/03/2005
Director appointment, Guido Van Dingenen (administrateur supplémentaire)
Director reappointment, Philippe Proost (director)
Director resignation, Frédéric Roch Doliveux (director)
Director appointment, Luc Vermeesch (director)
Mandate compensation, Guido Van Dingenen
Mandate compensation, Philippe Proost
Mandate compensation, Luc Vermeesch

2004

16-07

State Gazette act Resignation: A. Geeraerts (director)

Reappointment: D. Goossens (statutory auditor)3 facts ▸

General meeting, 16/03/2004
Director resignation, A. Geeraerts (director)
Director reappointment, D. Goossens (statutory auditor)

24-05

State Gazette act Capital & shares

Capital1 fact ▸

Capital, €1.000.000

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.An act published in both Dutch and French appears here once.

Directors · office · real estate

Directors

11 directors, no change since 2026

Jacques Marbehant

Director · since 01-07-2026

Current

Myriam Juckler

Déléguée chargée de la gestion journalière · since 26-07-2024

Current

Geoffroy Folie

Délégué chargé de la gestion journalière · since 19-10-2020

Current

Caroline Vancoillie

Director · since 09-05-2018

Current

Jean-Christophe Tellier

Director · since 17-03-2014

Current

Iris Loëw-Fredrich

Director

Not recently confirmed

5 other directors

Didier MALHERBE

Managing director · since 21-03-2006

Not recently confirmed

Simon Looman

Director

Not recently confirmed

Nicolas Gouwy

Manager qui assurera la gestion journalière · since 16-02-2005

Not recently confirmed

Guido Van Dingenen

Administrateur supplémentaire · since 15-03-2005

Not recently confirmed

Philippe Proost

Director · since 15-03-2005

Not recently confirmed

01-07-2026 Jacques Marbehant: Appointed as Director

30-06-2026 Kirsten Lund-Jürgensen: Resigned as Director

26-07-2024 Jacques Marbehant: Resigned as Daily management delegate

26-07-2024 Myriam Juckler: Appointed as Déléguée chargée de la gestion journalière

04-08-2023 Charl van Zyl: Reappointed as Director

Full history in the Timeline (59 changes) →

Location & real-estate footprint

Registered office, Anderlecht · 3 establishment units since 1968

establishment approximate All 3 establishment units on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Researchdreef 601070 Anderlecht

Ground area

23.9 ha

Building footprint

7,411 m²

Volume, LiDAR

59,155 m³

3 parcels, Brussels, Flanders, Wallonia · tallest building 18.7 m, ±4 floors. Linked by address, not a title deed.

3 establishment units

UCB PHARMA

Researchdreef 60, 1070 AnderlechtNACE 51460

since 19682.037.631.587

UCB PHARMA

Chemin du Foriest /, 1420 Braine-l'AlleudManufacture of basic metals

since 20062.159.107.459

UCB Pharma

Gaston Geenslaan 14, 3001 LeuvenScientific research and development

since 20232.342.005.216

3 parcels

Flanders 1 (33.3%) Wallonia 1 (33.3%) Brussels 1 (33.3%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
25743G0274/00E002	Wallonia	18.8 ha	1 · 1,486 m²	9.4 m · 2 fl.
21307F0123/00P000	Brussels	3.9 ha	1 · 4,201 m²	18.7 m · 4 fl.
24040B0224/00B000	Flanders	1.2 ha	1 · 1,724 m²	-

Linked by address, not proof of ownership

Methodology

via registered seat: 1 · via establishment units: 2

3 of 3 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor

Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRLCurrent

Commissaire aux comptes · represented by Sébastien Schueremans

26-08-2024 → present

Show 6 earlier auditors

D. Goossens Statutory auditor	- → 16-07-2004
Daniel Goossens Statutory auditor succeeded by SCCRL PwC Réviseurs d'Entreprises in 2012	08-06-2007 → 11-06-2012
Forvis Mazars Réviseurs d’Entreprises Statutory auditor succeeded by Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL in 2024	09-07-2021 → 26-08-2024
PwC Réviseurs d'Entreprises SRL Statutory auditor succeeded by Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL in 2024	09-07-2021 → 26-08-2024
SC SRL PwC Reviseurs d'Entreprises Statutory auditor · represented by Romain Seffer succeeded by PwC Réviseurs d'Entreprises SRL in 2021	09-06-2015 → 09-07-2021
SCCRL PwC Réviseurs d'Entreprises Statutory auditor · represented by Jean Fossion succeeded by SC SRL PwC Reviseurs d'Entreprises in 2015	11-06-2012 → 09-06-2015

Articles of association

Purpose

La recherche, la fabrication, le conditionnement, la transformation, l’achat et la vente, tant en Belgique qu’à l’étranger, de tous produits pharmaceutiques, thérapeutiques…

Full purpose

La recherche, la fabrication, le conditionnement, la transformation, l’achat et la vente, tant en Belgique qu’à l’étranger, de tous produits pharmaceutiques, thérapeutiques, cosmétiques, diététiques, à usage humain, végétal, animal, biologiques, produits chimiques, de tous matériels et instruments médicaux et chirurgicaux. Elle pourra faire toutes opérations industrielles, commerciales, financières ou civiles ayant un rapport direct ou indirect avec son objet...

according to the deed of 30-12-2020

Structure & network

Connections & network

7 connected companies

Shared directors

Linked via shared directors

Solvac

via Jean-Christophe Tellier · Director

→

ACCESS & PARTNERS

Shared director

→

Cadastre et Inspection Télévisuelle des réseaux

Shared director

→

FEDERATION BELGE DES INDUSTRIES CHIMIQUES ET DES SCIENCES DE LA VIE

Shared director

→

Show 3 more companies with a shared director

FONDS DE PREVOYANCE UCB - VOORZORGSFONDS UCB

Shared director

→

UCB BIOPHARMA

Shared director

→

UMICORE FINANCIAL SERVICES

Shared director

→

Ownership & control

1 parent company · 1 subsidiary, 1 abroad · 1 board mandate

Control over this companyparent company per the LEI register1

U C B

Anderlecht

controls

UCB PHARMABE 0403.096.168

controls

Where this company holds controlsubsidiary per the LEI register1

UCB PHARMA GMBH

Monheim Am Rhein, Germany

Board mandates of this companythis company sits on their board1

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

1 location

Capital and shareholders

Shareholders according to the acts

After the capital increase act of 30-12-2020 ↗

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years

28-07-2022 Capital increase of 819,225,260.40 EUR · to 7,804,773,797.45 EUR
22-01-2021 Capital stated in the act · 6,985,548,537.05 EUR · 839,351,526 shares
30-12-2020 Capital increase of 5,751,269,288.48 EUR · to 6,985,548,537.05 EUR
03-05-2019 Capital increase of 305,116,347.97 EUR · to 1,234,279,248.57 EUR
11-04-2016 Capital increase of 234,701,369.60 EUR · to 929,162,900.60 EUR
04-06-2010 Capital increase of 500,000,000 EUR · to 893,044,625 EUR · “sans création d'actions nouvelles”, “mais par augmentation du pair comptable des actions existantes”
04-06-2010 Capital reduction of 198,583,094 EUR · to 694,461,531 EUR · to absorb losses
15-06-2009 Capital increase of 359,000,000 EUR · to 752,044,625 EUR · “sans création d'actions nouvelles”, “mais par augmentation du pair comptable des actions existantes”

Show 2 older capital entries

15-06-2009 Capital reduction of 359,000,000 EUR · to 393,044,625 EUR · to absorb losses
24-05-2004 Capital stated in the act · 1,000,000 EUR

Public money · subsidies and aid

European research

28 projects · 1 as coordinator · 1,471,922 EUR EU contribution

Programmes

Seventh Framework Programme

19 entries · 1,221,362 EUR

Horizon 2020

5 entries · 250,560 EUR

Horizon Europe

5 entries

Projects

Foldamers against protein-protein interactions

Seventh Framework Programme · participant · 01-02-2009 to 31-01-2014 · 415,422 EUR · FOLDAPPI

Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems)

Horizon 2020 · participant · 01-01-2015 to 31-12-2018 · 250,560 EUR · eCHO Systems

Monoclonal ANTIbody-targeted CARBon nanobues against cancer

Seventh Framework Programme · participant · 01-03-2008 to 31-08-2011 · 204,000 EUR · ANTICARB

New Molecular Purification Technology for Pharmaceutical Production

Seventh Framework Programme · participant · 01-09-2008 to 31-08-2012 · 197,102 EUR · NEMOPUR

Virtual, Physiological and Computational Neuromuscular Models for the Predictive Treatment of Parkinson's\nDisease

Seventh Framework Programme · participant · 01-01-2014 to 31-12-2016 · 178,390 EUR · NoTremor

Show 23 more projects

Integrating research training in particle & powder technology to deliver efficient products with high functionality

Seventh Framework Programme · participant · 01-03-2011 to 28-02-2015 · 169,097 EUR · POWTECH

Continuous Catalytic Transformations: from optimization in MICRO systems to INDustrial production

Seventh Framework Programme · coordinator · 01-09-2013 to 31-08-2017 · 57,351 EUR · CCT-MicroIndus

The GEne Therapy INnovation Training Network

Horizon Europe · associated partner · 01-09-2023 to 31-08-2027 · GET-IN

Advanced Multiscale Biological Imaging using European Infrastructures

Horizon Europe · associated partner · 01-10-2024 to 30-09-2029 · AMBER

FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE

Horizon Europe · associated partner · 01-05-2026 to 30-04-2029 · FORTIFY

Improving Drug Efficacy with next-generation AmorphouS materials and trained experts

Horizon Europe · associated partner · 01-11-2026 to 31-10-2030 · IDEAS

MOlecular BIodiscovery for Life sciences InTerdiscplinarY innovation

Horizon Europe · associated partner · 01-10-2026 to 30-09-2032 · MOBILITY

Engineering of new-generation protein secretion systems

Horizon 2020 · participant · 01-01-2015 to 31-12-2018 · ProteinFactory

ISOTOPIC LABELING FOR DRUG INNOVATION

Horizon 2020 · participant · 01-01-2016 to 31-12-2019 · ISOTOPICS

European Vascular Interventions and Therapeutic Innovation Network

Horizon 2020 · partner · 01-04-2016 to 31-03-2020 · EVOluTION

A new generation of microbial expression hosts and tools for the production of biotherapeutics and high-value enzymes

Horizon 2020 · participant · 01-01-2019 to 30-06-2023 · Secreters

bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis

Seventh Framework Programme · participant · 01-01-2010 to 30-06-2015 · MARCAR

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities

Seventh Framework Programme · participant · 01-01-2010 to 31-12-2016 · ETOX

Understanding chronic pain and improving its treatment

Seventh Framework Programme · participant · 01-10-2009 to 30-09-2015 · EUROPAIN

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development

Seventh Framework Programme · participant · 01-01-2010 to 31-12-2015 · PHARMA-COG

Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes

Seventh Framework Programme · participant · 01-10-2009 to 30-09-2015 · U-BIOPRED

Physical Activity as a Crucial Patient Reported Outcome in COPD

Seventh Framework Programme · participant · 01-09-2009 to 31-05-2016 · PRO- ACTIVE

Pharmaceutical Medicine Training Programme

Seventh Framework Programme · participant · 01-05-2009 to 30-04-2014 · PHARMATRAIN

European programme in Pharmacovigilance and Pharmacoepidemiology

Seventh Framework Programme · participant · 01-09-2009 to 30-06-2016 · EU2P

Drug Disease Model Resources

Seventh Framework Programme · participant · 01-03-2011 to 31-08-2016 · DDMORE

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk

Seventh Framework Programme · participant · 01-03-2012 to 28-02-2018 · ABIRISK

European Lead Factory

Seventh Framework Programme · participant · 01-01-2013 to 31-05-2018 · EUC²LID

European Bank for induced pluripotent Stem Cells

Seventh Framework Programme · participant · 01-01-2014 to 31-12-2017 · EBISC

Recognitions · licences · registrations

Food safety, FASFC

2 sites

Anderlecht2.037.631.587

1 permission

Toelating · Andere grootkeuken (bereiding - distributie maaltijden) · since 17-10-2012

Braine-l'Alleud2.159.107.459

1 permission

Toelating · Andere grootkeuken (bereiding - distributie maaltijden) · since 24-08-2009

Legal Entity Identifier

213800NECEZ2CC2BOR25

live in the LEI register

Similar companies · same sector, comparable size

Bayer

BE 0404.754.571

Machelen (Brab.) · Eq €5.53B

ABBOTT

BE 0403.044.007

Wavre · Eq €2.10B

Viatris International Supply Point

BE 0463.648.419

Hoeilaart · Eq €1.66B

Of 1,898 companies in sector 46460 we hold annual accounts for 1,116. 3 are within a factor 10 of this equity. See the whole sector

Company data · Crossroads Bank

Identification

Legal formPublic limited company

Founded01-02-1968

Fiscal year end31-12

Activities, NACEBEL 2025

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

46460Wholesale of pharmaceutical and medical goods

Sources

Crossroads Bank for EnterprisesNational Bank · 48 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.